20Med Therapeutics is a Dutch biotechnology company focused on the development of prophylactic and therapeutic vaccines. Based on its proprietary bioresponsive polymer nanoparticle technology 20Med is building a non-viral delivery platform for the rapid development of RNA and DNA based vaccines, with applications in infectious diseases and cancer.
Manufacturing of the polymeric nanoparticles is straightforward, scalable, and independent of the payload, enabling rapid development of a vaccine in case of an outbreak of an unknown disease. The ready-to-use platform is easily combined with mRNA, saRNA or DNA coding for relevant antigens. One step loading and formulation allows for the development of a lyophilized vaccine that has the potential to eliminate cold chain logistics.
Visit our careers page for more information